PE20121405A1 - Excipiente solubilizante para vacunas de virus completo inactivado - Google Patents
Excipiente solubilizante para vacunas de virus completo inactivadoInfo
- Publication number
- PE20121405A1 PE20121405A1 PE2012000455A PE2012000455A PE20121405A1 PE 20121405 A1 PE20121405 A1 PE 20121405A1 PE 2012000455 A PE2012000455 A PE 2012000455A PE 2012000455 A PE2012000455 A PE 2012000455A PE 20121405 A1 PE20121405 A1 PE 20121405A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- amount
- buffer
- refers
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION DE VACUNA QUE COMPRENDE: (A) UNA PREPARACION DE VIRUS INACTIVADO DE LA RABIA Y (B) UN EXCIPIENTE ESTABILIZADOR QUE COMPRENDE: i) UNA SOLUCION TAMPON TAL COMO TAMPON FOSFATO, TAMPON TRIS, TAMPON HEPES O MEZCLA DE LOS MISMOS; ii) UNA MEZCLA DE AMINOACIDOS ESENCIALES Y NO ESENCIALES TAL COMO SALES DE ARGININA O DE ACIDO GLUTAMICO EN UNA CANTIDAD ENTRE 0.5 Y 2.5 MG; iii) UN DISACARIDO TAL COMO MALTOSA; iv) UN POLIOL TAL COMO SORBITOL; v) UN AGENTE QUELANTE TAL COMO EDTA O UNA SAL DE LA MISMA EN UNA CANTIDAD ENTRE 0.01 Y 0.1 MG; vi) UREA O DERIVADO DE UREA EN UNA CANTIDAD ENTRE 0.3 Y 1.5 MG; vii) UN SURFACTANTE NO IONICO TAL COMO POLOXAMERO 188 EN UNA CANTIDAD ENTRE 0.001 Y 0.5 MG. EL PH DE LA COMPOSICION ESTA ENTRE 7.0 Y 10.0. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. LA COMPOSICION DE VACUNA ESTA LIBRE DE CUALQUIER PROTEINA EXOGENA DE ORIGEN ANIMAL, SOLAMENTE LAS PROTEINAS VIRALES REPRESENTAN POR LO MENOS 70% DE LAS PROTEINAS TOTALES DE DICHA COMPOSICION. EL EXCIPIENTE ESTABILIZADOR DE DICHA COMPOSICION PREVIENE LA FORMACION DE AGREGADOS Y/O LA DEGRADACION ESTRUCTURAL DE LAS PARTICULAS VIRALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0904795 | 2009-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121405A1 true PE20121405A1 (es) | 2012-11-02 |
Family
ID=42123015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000455A PE20121405A1 (es) | 2009-10-07 | 2010-10-07 | Excipiente solubilizante para vacunas de virus completo inactivado |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8557253B2 (es) |
| EP (2) | EP3915586A1 (es) |
| CN (1) | CN102281900B (es) |
| AR (2) | AR078558A1 (es) |
| AU (1) | AU2010304898B2 (es) |
| BR (1) | BR112012008000B1 (es) |
| ES (1) | ES2862910T3 (es) |
| MA (1) | MA33723B1 (es) |
| MX (1) | MX338300B (es) |
| PE (1) | PE20121405A1 (es) |
| PL (1) | PL2485766T3 (es) |
| PT (1) | PT2485766T (es) |
| RU (1) | RU2560675C2 (es) |
| WO (1) | WO2011042663A1 (es) |
| ZA (1) | ZA201202758B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
| FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
| BR112013005049A2 (pt) * | 2010-09-02 | 2016-05-31 | Sanofi Pasteur | estabilizador para a preparação de uma composição vacina da pólio seca injetável |
| CN107050445A (zh) * | 2011-05-26 | 2017-08-18 | 葛兰素史密丝克莱恩生物有限公司 | 灭活登革热病毒疫苗 |
| EP3744833A1 (en) | 2011-06-28 | 2020-12-02 | Leukocare Ag | Stabilisation method for viruses |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| US9480739B2 (en) * | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| US10736840B2 (en) | 2013-09-03 | 2020-08-11 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| WO2015059284A1 (en) | 2013-10-25 | 2015-04-30 | Leukocare Ag | A novel method for the production of stabile vaccines |
| AR099470A1 (es) * | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
| CN104548085B (zh) * | 2014-12-09 | 2018-01-19 | 吕宏亮 | 一种口蹄疫全病毒颗粒疫苗组合物及其制备方法和应用 |
| CN105816879A (zh) * | 2016-03-17 | 2016-08-03 | 广州市嘉合生物技术有限公司 | 用于提高冻干病毒疫苗在常温下保存的效力的冻干稳定剂 |
| WO2018050873A1 (en) * | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| CN109952372A (zh) | 2016-09-16 | 2019-06-28 | 白血球保健股份有限公司 | 获得有效用于疫苗接种或基因治疗的基于病毒载体的组合物的新方法 |
| US20190256551A1 (en) * | 2016-09-16 | 2019-08-22 | Leukocare Ag | A novel method of producing a liquid biopharmaceutical drug product |
| GB201815011D0 (en) * | 2018-09-14 | 2018-10-31 | Adaptimmune Ltd | Viral assay method |
| US20220193222A1 (en) * | 2018-11-30 | 2022-06-23 | Vaccine Stabilization Institute | Viral formulations containing amino acids |
| US20220401554A1 (en) * | 2019-11-07 | 2022-12-22 | Cornell University | Use of membrane inhibitors to enhance vaccine development against enveloped viruses |
| CN112245394B (zh) * | 2020-10-21 | 2022-10-11 | 成都柏奥特克生物科技股份有限公司 | 一种疫苗保护剂 |
| WO2023023371A1 (en) * | 2021-08-20 | 2023-02-23 | Vaccine Stabilization Institute | Formulations containing amino acids for stabilizing lipid enveloped viral and non-viral vectors |
| CN114377127B (zh) * | 2022-01-25 | 2023-10-24 | 天津市中升挑战生物科技有限公司 | 一种三联卵黄抗体制剂及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR952310A (fr) | 1946-09-20 | 1949-11-15 | Ford | Transmission par accouplement hydraulique jumelé |
| JPS577423B2 (es) | 1972-12-29 | 1982-02-10 | ||
| FR2505657A1 (fr) | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US5565209A (en) * | 1987-03-17 | 1996-10-15 | Akzo Nobel N.V. | Adjuvant mixture |
| FR2633518B1 (fr) | 1988-06-30 | 1991-03-22 | Merieux Inst | Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| FR2801900B1 (fr) | 1999-12-03 | 2004-02-27 | Pasteur Merieux Serums Vacc | Methode de production de cellules animales adherentes |
| AU2005227320B2 (en) | 2004-03-22 | 2010-06-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, National Insitutes Of Health | Cellular and viral inactivation |
| CN101095950B (zh) | 2006-06-30 | 2011-01-26 | 辽宁成大生物股份有限公司 | 一种稳定的人用狂犬病疫苗冻干制剂及其制备 |
| GB0615312D0 (en) * | 2006-08-02 | 2006-09-13 | Univ Dundee | Protein Solubilisation |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| FR2944292B1 (fr) | 2009-04-08 | 2013-08-23 | Sanofi Pasteur | Procede de purification du virus rabique |
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
-
2010
- 2010-10-06 US US12/899,492 patent/US8557253B2/en active Active
- 2010-10-07 BR BR112012008000-8A patent/BR112012008000B1/pt active IP Right Grant
- 2010-10-07 ES ES10781953T patent/ES2862910T3/es active Active
- 2010-10-07 WO PCT/FR2010/052111 patent/WO2011042663A1/fr active Application Filing
- 2010-10-07 PL PL10781953T patent/PL2485766T3/pl unknown
- 2010-10-07 PT PT107819534T patent/PT2485766T/pt unknown
- 2010-10-07 EP EP20215726.9A patent/EP3915586A1/fr active Pending
- 2010-10-07 AU AU2010304898A patent/AU2010304898B2/en active Active
- 2010-10-07 EP EP10781953.4A patent/EP2485766B1/fr active Active
- 2010-10-07 MX MX2012003935A patent/MX338300B/es active IP Right Grant
- 2010-10-07 RU RU2012118386/15A patent/RU2560675C2/ru active
- 2010-10-07 AR ARP100103658 patent/AR078558A1/es not_active Application Discontinuation
- 2010-10-07 CN CN2010800046791A patent/CN102281900B/zh active Active
- 2010-10-07 PE PE2012000455A patent/PE20121405A1/es active IP Right Grant
-
2012
- 2012-04-16 ZA ZA2012/02758A patent/ZA201202758B/en unknown
- 2012-05-03 MA MA34832A patent/MA33723B1/fr unknown
-
2013
- 2013-10-08 US US14/048,144 patent/US9028839B2/en active Active
-
2020
- 2020-03-06 AR ARP200100627A patent/AR118273A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140037684A1 (en) | 2014-02-06 |
| US9028839B2 (en) | 2015-05-12 |
| ZA201202758B (en) | 2013-06-26 |
| US8557253B2 (en) | 2013-10-15 |
| PT2485766T (pt) | 2021-03-18 |
| AU2010304898A1 (en) | 2012-05-17 |
| PL2485766T3 (pl) | 2021-09-06 |
| WO2011042663A1 (fr) | 2011-04-14 |
| CN102281900B (zh) | 2013-07-03 |
| RU2560675C2 (ru) | 2015-08-20 |
| EP2485766A1 (fr) | 2012-08-15 |
| EP3915586A1 (fr) | 2021-12-01 |
| RU2012118386A (ru) | 2013-11-20 |
| AR078558A1 (es) | 2011-11-16 |
| BR112012008000A2 (pt) | 2016-03-29 |
| MA33723B1 (fr) | 2012-11-01 |
| BR112012008000B1 (pt) | 2021-07-13 |
| MX2012003935A (es) | 2012-05-08 |
| EP2485766B1 (fr) | 2020-12-30 |
| AU2010304898B2 (en) | 2015-03-19 |
| ES2862910T3 (es) | 2021-10-08 |
| US20110081380A1 (en) | 2011-04-07 |
| AR118273A2 (es) | 2021-09-22 |
| CN102281900A (zh) | 2011-12-14 |
| MX338300B (es) | 2016-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121405A1 (es) | Excipiente solubilizante para vacunas de virus completo inactivado | |
| CL2011002918A1 (es) | Composicion farmaceutica solida que comprende al inhibidor de quinasa aurora acido 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico, una sal o una forma cristalina del mismo; metodo para prepararla que incluye un proceso de granulacion en humedo. | |
| PE20120342A1 (es) | Formulacion de anticuerpo | |
| AR079556A1 (es) | Formacion de anticuerpos | |
| BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| ECSP11010878A (es) | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. | |
| CL2021000863A1 (es) | Compuestos de aminoácidos y métodos de uso. | |
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| PA8774901A1 (es) | Productos de cuidado oral y metodos para usar y fabricar el mismo | |
| BR112014023869A2 (pt) | proteínas nutritivas carregadas e métodos | |
| AR086872A1 (es) | Composicion descongelante, proceso de preparacion, conjunto de partes y uso | |
| EA201171216A1 (ru) | Фенилацетат l-орнитина и способы его получения | |
| CL2008003794A1 (es) | Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular. | |
| BR112014002624A8 (pt) | Microorganismo recombinante e cultura de microorganismo recombinante | |
| CR20140053A (es) | Formulaciones de ácido desoxicólico y sales del mismo | |
| AR065640A1 (es) | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma | |
| IN2014MN01714A (es) | ||
| AR082776A1 (es) | Estabilizacion de hormona foliculo estimulante (fsh) | |
| AR085703A1 (es) | Composiciones detergentes multiuso | |
| BR112017016599A2 (pt) | concentrado de adjuvante aquoso, e, formulação de herbicida pulverizável. | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| GT201400027A (es) | Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina | |
| MX358770B (es) | Acopladores para acidos grasos de cadena media y composiciones desinfectantes. | |
| AR075097A1 (es) | Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia | |
| BR112021019612A2 (pt) | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |